title: Synthesis and antitumor efficacy of daunorubicin-loaded magnetic nanoparticles.
abstract: BACKGROUND
  A promising approach to optimize the disposition of daunorubicin-loaded magnetic nanoparticles (DNR-MNPs) was developed to minimize serious side effects of systematic chemotherapy for cancer.
  
  
  METHODS
  The physical properties of DNR-MNPs were investigated and their effect on leukemia cells in vitro was evaluated by a standard WST-1 cell proliferation assay. Furthermore, cell apoptosis and intracellular accumulation of DNR were determined by FACSCalibur flow cytometry.
  
  
  RESULTS
  Our results showed that the majority of MNPs were spherical and their sizes were from 10 to 20 nm. The average hydrodynamic diameter of DNR-MNPs in water was 94 nm. The in vitro release data showed that the DNR-MNPs have excellent sustained release property. Proliferation of K562 cells was inhibited in a dose-dependent manner by DNR in solution (DNR-Sol) or by DNR-MNPs. The IC(50) for DNR-MNPs was slightly higher than that for DNR-Sol. DNR-MNPs also induced less apoptosis in K562 cells than did DNR-Sol. Detection of fluorescence intensity of intracellular DNR demonstrated that DNR-MNPs could be taken up by K562 cells and persistently released DNR in cells.
  
  
  CONCLUSIONS
  Our study suggests that optimized DNR-MNPs formulation possesses sustained drug-release and favorable antitumor properties, which may be used as a conventional dosage form for antitumor therapy.
authors: Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.
authors: Jun
authors: J
authors: Wang
authors: Baoan
authors: B
authors: Chen
authors: Jian
authors: J
authors: Chen
authors: Xiaohui
authors: X
authors: Cai
authors: Guohua
authors: G
authors: Xia
authors: Ran
authors: R
authors: Liu
authors: Pingsheng
authors: P
authors: Chen
authors: Yu
authors: Y
authors: Zhang
authors: Xuemei
authors: X
authors: Wang
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D003630:Daunorubicin / Q000008:administration & dosage* / Q000737:chemistry; D003692:Delayed-Action Preparations / Q000008:administration & dosage; D006801:Humans; D020128:Inhibitory Concentration 50; D020014:K562 Cells / Q000187:drug effects*; D007938:Leukemia / Q000188:drug therapy*; D058185:Magnetite Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry / Q000648:ultrastructure; D046529:Microscopy, Electron, Transmission; D050997:Nanomedicine / Q000379:methods; D019301:Oleic Acid / Q000737:chemistry; D010316:Particle Size; D020442:Poloxamer / Q000737:chemistry
chemical_list: D003692:Delayed-Action Preparations; D058185:Magnetite Nanoparticles; D020442:Poloxamer; D019301:Oleic Acid; D003630:Daunorubicin